Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-64658

Happold, C; Roth, P; Wick, W; Schmidt, N; Florea, A M; Silginer, M; Reifenberger, G; Weller, M (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 122(2):444-455.

[img]
Preview
Accepted Version
PDF
249kB

View at publisher

Abstract

J. Neurochem. (2012) 10.1111/j.1471-4159.2012.07781.x ABSTRACT: Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma. Clinical benefit is more prominent in patients with methylation of the O(6) -methyl-guanine DNA methyltransferase (MGMT) promoter. However, all patients eventually suffer from tumor progression because their tumors become resistant to TMZ. Here, we modeled acquired TMZ resistance in glioma cells in vitro to identify underlying molecular mechanisms. To this end, the glioma cell lines LNT-229, LN-308, and LN-18 were exposed repetitively to increasing concentrations of TMZ to induce a stable resistant phenotype (R) defined by clonogenic survival assays. The molecular mechanisms mediating acquired resistance were assessed by immunoblot, PCR, and flow cytometry. Rescue experiments were performed with siRNA-mediated candidate gene silencing. We found in LN-18 cells constitutively expressing MGMT a strong up-regulation of MGMT levels in TMZ-resistant cells. TMZ resistance in the MGMT-negative cell lines LNT-229 and LN-308 was not associated with de novo expression of MGMT. Instead, we found a down-regulation of several DNA mismatch-repair proteins in resistant LNT-229 cells. A TMZ-resistant phenotype was also achieved by silencing selected DNA mismatch repair proteins in parental LNT-229 cells. No obvious mechanism of resistance was identified in the third cell line, LN-308, except for reduced methylation of LINE-1 repetitive elements. In conclusion, we demonstrate that different molecular mechanisms may contribute to the development of acquired TMZ resistance in glioma cells, indicating the need to develop distinct strategies to overcome resistance.

Citations

8 citations in Web of Science®
12 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

42 downloads since deposited on 08 Oct 2012
31 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:610 Medicine & health
Language:English
Date:2012
Deposited On:08 Oct 2012 13:17
Last Modified:27 Nov 2013 20:55
Publisher:Wiley-Blackwell
ISSN:0022-3042
Additional Information:The definitive version is available at www.onlinelibrary.com
Publisher DOI:10.1111/j.1471-4159.2012.07781.x
PubMed ID:22564186

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page